---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020843"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:55:06.279863+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bioventus Q1 revenue $129.5M (+8.7% YoY), guides FY24 higher

## Summary
- Net loss from continuing ops $6.0M vs $100.0M prior year; diluted loss per share $0.07 vs $1.28.
- Pain Treatments revenue $56.7M (+23.5% US); Surgical Solutions revenue $42.3M (+19.0% US).
- Adjusted EBITDA $22.6M, up 33.5% YoY; adjusted gross margin expanded 190 bps.
- FY 2024 guidance raised: net sales $535-550M, Adj. EBITDA $94-99M, Non-GAAP EPS $0.25-0.33.
- Organic revenue growth 15.3% driven by Pain Treatments and Surgical Solutions.

## SEC filing metadata
- accession: 0001628280-24-020843
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/bvs-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020843
- JSON: https://secwatch.observer/filing/0001628280-24-020843.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020843.txt

## Key facts
- Earnings Releases
  Bioventus Inc. reported three months ended March 30, 2024 results: revenue $129.5 million, net income net loss from continuing operations of $6.0 million, EPS Loss per share of Class A common stock from continuing operations was $0.07.
  - Period: three months ended March 30, 2024
  - Revenue: $129.5 million
  - Net income: net loss from continuing operations of $6.0 million
  - EPS: Loss per share of Class A common stock from continuing operations was $0.07
  - Result: reported results
  source text: For the first quarter, worldwide revenue totaled $129.5 million, an increase of 8.7% compared to the prior-year period. On an organic* basis, revenue increased 15.3%, driven by growth in Pain Treatments and Surgical Solutions. The Company also reported a first quarter net loss from continuing operations of $6.0 million, compared to a net loss from continuing operations of $100.0 million in the prior-year period. Adjusted EBITDA* from continuing operations totaled $22.6 million, advancing 33.5%, compared to the prior year total of $17.0 million due to strong revenue growth and increased gross margin. Loss per share of Class A common stock from continuing operations was $0.07 in the first quarter, compared to a loss of $1.28 in the prior-year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm
- Earnings Releases
  Bioventus Inc. reported full-year 2024 results: revenue $535 million to $550 million, EPS $0.25 to $0.33. Guidance raised.
  - Period: full-year 2024
  - Revenue: $535 million to $550 million
  - EPS: $0.25 to $0.33
  - Guidance: raised
  - Result: guidance update
  source text: Based on strong execution and significant momentum across the business, Bioventus is raising financial guidance for full-year 2024. The Company now expects: • Net sales of $535 million to $550 million—An increase of $15 million from previous guidance • Adjusted EBITDA* of $94 million to $99 million—An increase of $5 million from previous guidance • Non-GAAP EPS* of $0.25 to $0.33—An increase of $0.13 from previous guidance
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000162828024020843/0001628280-24-020843-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.